Biotech · Private company · Olathe, KS, US
TVAX Biomedical
Track this companyFree. Adds TVAX Biomedical to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- RadiotherapyPhase 3 · Glioblastoma Multiforme of BrainClinicalTrials.gov · fetched Nov 12, 2026
- TemozolomidePhase 3 · Glioblastoma Multiforme of BrainClinicalTrials.gov · fetched Nov 12, 2026
- TVI-Brain-1Phase 3 · Glioblastoma Multiforme of BrainClinicalTrials.gov · fetched Nov 12, 2026
- Cancer vaccine plus immune adjuvantPhase 2 · GliomaClinicalTrials.gov · fetched Nov 12, 2026
- TVI-Brain-1Phase 2 · Grade IV GliomaClinicalTrials.gov · fetched Nov 12, 2026
- TVI-Brain 1Recurrent GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)PHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Dec 27, 2023ClinicalTrials.gov NCT05685004 · fetched Nov 12, 2026
- Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV GliomaPHASE2 · COMPLETED · started Jun 1, 2011ClinicalTrials.gov NCT01290692 · fetched Nov 12, 2026
- Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV GliomaPHASE1_PHASE2 · COMPLETED · started Apr 1, 2010ClinicalTrials.gov NCT01081223 · fetched Nov 12, 2026
- TVI-Brain-1 in Expanded Access PatientNO_LONGER_AVAILABLEClinicalTrials.gov NCT05936216 · fetched Nov 12, 2026
NIH awards1
- Neoantigen-specific Adoptive T Cell Therapy for Glioblastoma, IND-BB-13135, protocol submitted 04/25/2020Fiscal year 2025 · $391.4KNIH RePORTER 5R01FD007259-02 · fetched Nov 12, 2026